comparemela.com

Oral Sulopenem News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call Transcript

Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections Clinical Trial Expected to Begin Enrollment in Q4 2022 DUBLIN,.

Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

25.04.2022 - DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused . Seite 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.